iBGStar® From Sanofi Was The Star Of The Latest ADA Scientific Sessions
by R. Keith Campbell Rph, FAADE, CDE
I have attended 43 of the past 45 Scientific Sessions of the American Diabetes Association. It is the best meeting to attend to keep up to date with the latest developments in the treatment of diabetes. I especially enjoy the exhibits and seeing what new products and devices are being shown. Before 1995, there were very few exhibitors since the main products to treat diabetes were insulin and sulfonylureas and blood glucose meters. We now have over 14 classes of drugs to treat diabetes, primarily type 2 diabetes. We also have had an explosion of companies selling insulin pumps, products to treat low blood sugars, diabetes complications, and new versions of blood glucose meters that are easier to use, smaller, more accurate and do not require calibration.
After spending many hours visiting each exhibitor, I concluded that the star (hit) of the meeting this year was the iBGStar® from Sanofi. It is a small blood glucose meter that is easy to use and effortlessly and quickly fits into one's Apple iPhone® or iPod touch®. A patient or health care provider can attach the meter to the iPhone, get a drop of blood and place it on the strip that was placed into the device and—yippee skippee—a blood glucose value appears! This value is then stored and analyzed and one can over time get reports of blood glucose values. It measures blood glucose levels between 20 and 600 mg/dL. Maybe I was impressed because I recently got an iPhone®. People who saw the device were stating that they were going to go buy an iPhone® or iPod touch® so they could use the device. I can easily carry the iBGStar® and test whenever I need to. I find I am testing more often and the analysis of the data is helping me better manage my blood glucose levels.
Overall, it was a great meeting for Sanofi since the ORIGIN study was presented that showed that their insulin, Lantus®, did not increase the risk of cancer. It also showed that early use of once daily Lantus® led to sustainable glycemic control, very low rates of hypoglycemia, a neutral effect on cardiovascular outcomes and reduced the progression from pre-diabetes to diabetes. Other news from the meeting presented information about a new basal insulin that will compete with Lantus that should soon be FDA approved called degludec from Novo Nordisk. Lilly also reported on a basal insulin that they have in development. It appears that there will soon be a new class of drugs called SGLT2 Inhibitors available to treat diabetes. This class of drugs block the re-uptake of glucose in the kidney causing one to urinate out the glucose. Patients lose weight and significantly lower their blood glucose levels and also lower their blood pressure. For obese type 2 patients, numerous reports showed many benefits from bariatric surgery in actually normalizing blood glucose levels and getting patients to lose weight.
The meeting was great, as usual. I always leave the meeting with a feeling that “the more we know, the more we know that there is much more to know”. Watch the diabetes literature for even more reports of news about developments in diabetes care.
About The Author
R. Keith Campbell RPh, FAADE, CDE is a leader in the field of diabetes, named the “Outstanding Health Care Educator in the Field of Diabetes in the U.S.” by the American Diabetes Association, having published more than 650 articles, serving on numerous boards (including the American Association of Diabetes Educators), and co-developing the popular CADD ambulatory infusion pump.
The views and opinions expressed in this blog are solely those of the author, and do not represent the views of DiabetesProductSource, Kestrel Health Information, Inc., its affiliates, or subsidiary companies.